查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495360

全球糖组学治疗市场：产业分析、规模、占有率、成长、趋势、预测（2024-2032）

Glycomic Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 306 Pages | 商品交期: 2-5个工作天内

价格
简介目录

本报告对全球糖组学治疗市场进行了深入分析，并深入瞭解其复杂的动态和未来轨迹。从市场趋势到成长催化剂、抑制剂和新兴模式，我们提供 2024 年至 2032 年有价值的统计数据和预测。

关键见解

  • 糖组学治疗市场规模（2024 年）：167,615,670,000 美元
  • 预测市场规模（2032 年）5,517.56 亿美元
  • 全球市场成长率（2024-2032 年复合年增长率）：16.1%

糖组学治疗市场 - 报告范围：

糖组治疗市场包括製药、生物技术和医疗保健等行业的各种应用。糖组学疗法涉及研究和操纵聚醣（糖）以达到治疗目的。这些疗法在疫苗、癌症治疗和传染病治疗的开发中发挥重要作用。该市场服务于广泛的最终用户，包括製药公司、生物技术公司和研究机构，为疾病治疗和预防提供先进的解决方案。市场成长是由技术进步、针对性治疗需求增加以及医疗保健研究投资增加等因素所推动的。

市场驱动因素：

全球糖组学治疗市场受到几个关键成长动力的支持。糖组学的技术进步将增强对聚醣的理解和操纵，并促进新疗法的开发。此外，对标靶和个人化医疗不断增长的需求正在创造对血糖治疗的巨大需求。此外，增加对医疗保健研发的投资将刺激聚醣新治疗应用的发现，进一步推动市场成长。

市场限制因素：

儘管成长前景广阔，但糖组学治疗市场面临着与高研发成本、监管障碍和替代疗法竞争相关的课题。由于聚醣结构和功能的复杂性，研发需要大量投资，为进入市场的公司带来了财务课题。治疗药物开发和批准的严格监管要求增加了合规负担并影响市场扩张。此外，来自基因组学和蛋白□□质组学等其他治疗方法的竞争对糖组学治疗的广泛使用提出了课题。

市场机会：

由于技术创新、产业联盟和市场多元化，糖组学治疗市场提供了利润丰厚的成长机会。个人化医疗、免疫疗法和合成生物学等新兴趋势正在促使製造商探索糖组治疗的新配方和应用。此外，透过策略合作、联合研究和併购，市场参与者正在扩大产品组合，增强技术能力，并加强在关键地区的市场占有率。此外，增加对医疗保健研究的投资以及政府对技术创新和工业基础设施的支持力度加大，正在创造有利于市场扩张和多元化的环境。

本报告涵盖的主要问题

  • 推动全球糖组学治疗市场成长的关键因素是什么？
  • 技术进步和产业趋势如何影响糖组学治疗应用和配方的演变？
  • 糖组治疗领域的市场参与者面临哪些主要课题与机会？
  • 哪些产业和地区为糖疗法製造商提供了最高的成长潜力？
  • 领先公司正在采取哪些策略来实现糖组治疗的差异化并在竞争格局中赢得市场占有率？

目录

第 1 章执行摘要

第二章市场概述

  • 市场范围/分类
  • 市场定义/范围/限制

第三章市场背景

  • 市场动态
  • 情境预测
  • 机会图分析
  • 投资可行性矩阵
  • PESTLE 和 Porter 分析
  • 监理状况
  • 区域母公司市场前景

第四章全球醣组学治疗市场分析

  • 2019-2023 年过去的市场规模金额（百万美元）分析
  • 2024-2032 年当前及未来市场规模金额（百万美元）预测
    • 年成长趋势分析
    • 绝对的$机会分析

第 5 章全球醣组学治疗市场分析：依类别

  • 简介/主要发现
  • 2019-2023 年依类别划分的市场规模金额（百万美元）绩效分析
  • 2024-2032 年当前和未来市场规模价值（百万美元）的分析和预测（依类别）
    • 隔离
    • 合成
  • 年成长趋势分析：依类别，2019-2023 年
  • 绝对美元机会分析：依类别划分，2024-2032 年

第 6 章全球醣组学治疗市场分析：依适应症

  • 简介/主要发现
  • 2019-2023 年依适应症划分的市场规模（百万美元）绩效分析
  • 2024-2032 年当前和未来市场规模价值（百万美元）的分析和预测（依指标）
    • 血栓形成/化学预防
    • 贫血
    • 抗沾黏/抗发炎特性
    • 白内障
    • 戈谢病
    • MPS-1□IV
    • 癌症
    • 阿兹海默症
    • A/B 型流感
    • 其他
  • 年成长趋势分析：依指标划分，2019-2023 年
  • 绝对机会分析：依迹象划分，2024 年至 2032 年

第 7 章全球糖组学治疗市场分析：依结构

  • 简介/主要发现
  • 2019-2023 年依结构划分的市场规模金额（百万美元）实际分析
  • 2024-2032 年当前和未来市场规模价值（百万美元）的分析和预测（依结构）
    • 糖蛋白
    • 标靶唾液酸
    • 扎那米韦
    • 奥司他韦
    • 蛋白多醣
    • 糖基磷脂□肌醇 - 锚定蛋白和肝素聚醣
    • 标靶醣胺聚醣
    • 标靶醣脂
    • 其他 - 阿卡波糖、α-葡萄糖甘□、阿洛□
  • 年成长趋势分析：依结构划分，2019-2023 年
  • 绝对美元机会分析：依结构划分，2024-2032 年

第 8 章全球醣组学治疗市场分析：依作用机转

  • 简介/主要发现
  • 2019-2023 年依作用机制划分的市场规模（百万美元）绩效分析
  • 依作用机制分析与预测 2024-2032 年当前及未来市场规模价值（百万美元）
    • 抑制神经氨酸□
    • 促红血球生成素和酵素替代疗法 - ERT
    • 组织纤溶□原激活剂
    • 抑制葡萄糖神经酰胺合成□
    • 白血球介素 1、2、3
    • β和γ干扰素
  • 年成长趋势分析：依作用机制，2019-2023 年
  • 绝对机会分析：依行动方式，2024-2032 年

第 9 章全球糖组学治疗市场分析：依地区

  • 简介/主要发现
  • 2019-2023 年依地区划分的市场规模金额（百万美元）绩效分析
  • 2024-2032 年依地区划分的当前和未来市场规模价值（百万美元）分析和预测
    • 北美
    • 拉丁美洲
    • 欧洲
    • 亚太地区
    • 中东/非洲
  • 市场吸引力分析：依地区划分

第 10 章北美糖组学治疗市场分析：依国家

第 11 章拉丁美洲糖组学治疗市场分析：依国家

第 12 章欧洲糖组学治疗市场分析：依国家

第 13 章亚太地区糖组学治疗市场分析：依国家

第 14 章中东和非洲糖组学治疗市场分析：依国家

第十五章主要国家糖组学治疗市场分析

  • 美国
  • 加拿大
  • 巴西
  • 墨西哥
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 中国
  • 日本
  • 韩国
  • 新加坡
  • 泰国
  • 印尼
  • 澳大利亚
  • 纽西兰
  • 海湾合作委员会国家
  • 南非
  • 以色列

第十六章市场结构分析

  • 竞争对手仪表板
  • 竞争基准
  • 主要公司市占率分析

第十七章竞争分析

  • 衝突详情
    • Intellihep Ltd
    • Protalix Biotherapeutics
    • BioMarin Pharmaceutical Inc.
    • Sanofi
    • Halozyme Therapeutics Inc
    • Bayer AG
    • Alzheon Inc.
    • GlycoMar
    • GlaxoSmithKline Plc
    • F. Hoffmann-La Roche Ltd

第 18 章使用的假设与缩写

第 19 章研究方法

简介目录
Product Code: PMRREP33227

Persistence Market Research presents an in-depth analysis of the Glycomic Therapeutics Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2032.

Key Insights:

  • Glycomic Therapeutics Market Size (2024): USD 167615.67 Million
  • Projected Market Value (2032): USD 551756 Million
  • Global Market Growth Rate (CAGR 2024 to 2032): 16.1%

Glycomic Therapeutics Market - Report Scope:

The Glycomic Therapeutics Market encompasses various applications across industries such as pharmaceuticals, biotechnology, and healthcare. Glycomic therapeutics involve the study and manipulation of glycans (sugars) for therapeutic purposes. These therapeutics play a crucial role in the development of vaccines, cancer treatments, and therapies for infectious diseases. This market caters to a wide range of end-users, including pharmaceutical companies, biotech firms, and research institutions, offering advanced solutions for disease treatment and prevention. Market growth is driven by factors such as technological advancements, increasing demand for targeted therapies, and rising investment in healthcare research.

Market Growth Drivers:

The global Glycomic Therapeutics Market is bolstered by several key growth drivers. Technological advancements in glycomics enhance the understanding and manipulation of glycans, driving the development of novel therapeutics. Moreover, the increasing demand for targeted and personalized medicine creates significant demand for glycomic therapeutics. Additionally, the growing investment in healthcare research and development stimulates the discovery of new therapeutic applications for glycans, further propelling market growth.

Market Restraints:

Despite its promising growth prospects, the Glycomic Therapeutics Market faces challenges related to high research and development costs, regulatory hurdles, and competition from alternative therapies. The complexity of glycan structures and functions requires substantial investment in research and development, posing financial challenges for market players. Stringent regulatory requirements regarding therapeutic development and approval impose compliance burdens, impacting market expansion. Furthermore, competition from other therapeutic approaches, such as genomics and proteomics, poses challenges to the widespread adoption of glycomic therapeutics.

Market Opportunities:

The Glycomic Therapeutics Market presents lucrative growth opportunities driven by technological innovation, industry collaborations, and market diversification. Emerging trends such as personalized medicine, immunotherapy, and synthetic biology inspire manufacturers to explore new formulations and applications for glycomic therapeutics. Moreover, strategic partnerships, research collaborations, and mergers and acquisitions enable market players to expand their product portfolios, enhance their technical capabilities, and strengthen their market presence in key regions. Furthermore, growing investments in healthcare research, coupled with increasing government support for innovation and industrial infrastructure, create a conducive environment for market expansion and diversification.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Glycomic Therapeutics Market globally?
  • How are technological advancements and industry trends shaping the evolution of glycomic therapeutics applications and formulations?
  • What are the key challenges and opportunities facing market participants in the glycomic therapeutics segment?
  • Which industrial sectors and geographic regions offer the highest growth potential for glycomic therapeutics manufacturers?
  • What strategies are leading companies employing to differentiate their glycomic therapeutics offerings and capture market share in the competitive healthcare landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Glycomic Therapeutics Market, including pharmaceutical companies, biotech firms, and research institutions, focus on innovation, product differentiation, and market expansion to gain a competitive edge. These companies invest in research and development to develop advanced glycan manipulation technologies, improve therapeutic efficacy, and explore new applications for glycomic therapeutics. Moreover, strategic collaborations with research institutions, academic partners, and industry associations enable market players to access new technologies, expand their knowledge base, and accelerate product development efforts. Furthermore, emphasis on regulatory compliance, quality assurance, and customer support enhances brand reputation and fosters long-term relationships with customers and stakeholders.

Key Companies Profiled:

  • GlycoMimetics, Inc.
  • Protalix BioTherapeutics, Inc.
  • Angion Biomedica Corp.
  • Oxford GlycoSciences Ltd.
  • GlycoNet
  • GlycoThera GmbH
  • Z Biotech, LLC
  • Sanguine BioSciences, Inc.
  • GLYcoDiag
  • Genentech, Inc.
  • Novartis AG
  • Eli Lilly and Company

Glycomic Therapeutics Market Research Segmentation:

By Class:

  • Isolated
  • Synthetic

By Structures:

  • Glycoproteins
  • Targeting Sialic Acid
  • Proteoglycans
  • Targeting Glycosaminoglycans
  • Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  • Targeting Glycosphingolipids
  • Others

By Indications:

  • Thrombosis and Chemoprophylaxis
  • Anaemia
  • Anti-adhesive and Anti-inflammatory
  • Cataracts
  • Gaucher's disease
  • MPS-1 and IV
  • Cancer
  • Alzheimer's disease
  • Influenza type A and B
  • Others

By Mode of Action:

  • Inhibits Neuraminidase
  • Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  • Erythropoietin and Enzyme Replacement Therapy
  • Tissue Plasminogen Activator
  • Inhibits Glucosylceramide Synthase
  • Interleukin 1, 2 & 3
  • Beta and Gamma Interferons
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Technology Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Background

  • 3.1. Market Dynamics
    • 3.1.1. Drivers
    • 3.1.2. Restraints
    • 3.1.3. Opportunity
    • 3.1.4. Trends
  • 3.2. Scenario Forecast
    • 3.2.1. Demand in Optimistic Scenario
    • 3.2.2. Demand in Likely Scenario
    • 3.2.3. Demand in Conservative Scenario
  • 3.3. Opportunity Map Analysis
  • 3.4. Investment Feasibility Matrix
  • 3.5. PESTLE and Porter's Analysis
  • 3.6. Regulatory Landscape
    • 3.6.1. By Key Regions
    • 3.6.2. By Key Countries
  • 3.7. Regional Parent Market Outlook

4. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast, 2024-2032

  • 4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
  • 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2032
    • 4.2.1. Y-o-Y Growth Trend Analysis
    • 4.2.2. Absolute $ Opportunity Analysis

5. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Class

  • 5.1. Introduction / Key Findings
  • 5.2. Historical Market Size Value (US$ Mn) Analysis By Class, 2019-2023
  • 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Class, 2024-2032
    • 5.3.1. Isolated
    • 5.3.2. Synthetic
  • 5.4. Y-o-Y Growth Trend Analysis By Class, 2019-2023
  • 5.5. Absolute $ Opportunity Analysis By Class, 2024-2032

6. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Indication

  • 6.1. Introduction / Key Findings
  • 6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2019-2023
  • 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2024-2032
    • 6.3.1. Thrombosis and Chemoprophylaxis
    • 6.3.2. Anaemia
    • 6.3.3. Anti-adhesive and Anti-inflammatory
    • 6.3.4. Cataract
    • 6.3.5. Gaucher's Diseases
    • 6.3.6. MPS-1 & IV
    • 6.3.7. Cancer
    • 6.3.8. Alzheimer's
    • 6.3.9. Influenza Type A and B
    • 6.3.10. Others
  • 6.4. Y-o-Y Growth Trend Analysis By Indication, 2019-2023
  • 6.5. Absolute $ Opportunity Analysis By Indication, 2024-2032

7. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Structures

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size Value (US$ Mn) Analysis By Structures , 2019-2023
  • 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Structures , 2024-2032
    • 7.3.1. Glycoproteins
    • 7.3.2. Targeting Sialic Acid
    • 7.3.3. Zanamivir
    • 7.3.4. Oseltamivir
    • 7.3.5. Proteoglycans
    • 7.3.6. Glycosylphosphatidylinositol - Anchored Proteins and Heparin Based Glycans
    • 7.3.7. Targeting Glycosaminoglycans
      • 7.3.7.1. Heparin
      • 7.3.7.2. Hyaluronan - HA
      • 7.3.7.3. Laronidase
      • 7.3.7.4. Galsulfase - Naglazyme
      • 7.3.7.5. Hyaluronidase - Cumulase
      • 7.3.7.6. Others
    • 7.3.8. Targeting Glycosphingolipids
      • 7.3.8.1. Imiglucerase - Cerezyme
      • 7.3.8.2. Agalsidase - Fabrazyme
      • 7.3.8.3. N-butyl-deoxynojirimycin - DNJ
      • 7.3.8.4. Others
    • 7.3.9. Others - Acarbose, Alglucosidase Alfa, Allosamidin
  • 7.4. Y-o-Y Growth Trend Analysis By Structures , 2019-2023
  • 7.5. Absolute $ Opportunity Analysis By Structures , 2024-2032

8. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Mode of Action

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size Value (US$ Mn) Analysis By Mode of Action, 2019-2023
  • 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Mode of Action, 2024-2032
    • 8.3.1. Inhibits Neuraminidase
    • 8.3.2. Erythhropoietin and Enzyme Replacement Therapy - ERT
    • 8.3.3. Tissue Plasminogen Activator
    • 8.3.4. Inhibits Glucosylceramide Synthase
    • 8.3.5. Interleukin 1 and 2 and 3
    • 8.3.6. Beta and Gamma Interferons
    • 8.3.7. Others
  • 8.4. Y-o-Y Growth Trend Analysis By Mode of Action, 2019-2023
  • 8.5. Absolute $ Opportunity Analysis By Mode of Action, 2024-2032

9. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. MEA
  • 9.4. Market Attractiveness Analysis By Region

10. North America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 10.2.1. By Country
      • 10.2.1.1. U.S.
      • 10.2.1.2. Canada
    • 10.2.2. By Class
    • 10.2.3. By Indication
    • 10.2.4. By Structures
    • 10.2.5. By Mode of Action
  • 10.3. Market Attractiveness Analysis
    • 10.3.1. By Country
    • 10.3.2. By Class
    • 10.3.3. By Indication
    • 10.3.4. By Structures
    • 10.3.5. By Mode of Action
  • 10.4. Key Takeaways

11. Latin America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 11.2.1. By Country
      • 11.2.1.1. Brazil
      • 11.2.1.2. Mexico
      • 11.2.1.3. Rest of Latin America
    • 11.2.2. By Class
    • 11.2.3. By Indication
    • 11.2.4. By Structures
    • 11.2.5. By Mode of Action
  • 11.3. Market Attractiveness Analysis
    • 11.3.1. By Country
    • 11.3.2. By Class
    • 11.3.3. By Indication
    • 11.3.4. By Structures
    • 11.3.5. By Mode of Action
  • 11.4. Key Takeaways

12. Europe Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 12.2.1. By Country
      • 12.2.1.1. Germany
      • 12.2.1.2. U.K.
      • 12.2.1.3. France
      • 12.2.1.4. Spain
      • 12.2.1.5. Italy
      • 12.2.1.6. Rest of Europe
    • 12.2.2. By Class
    • 12.2.3. By Indication
    • 12.2.4. By Structures
    • 12.2.5. By Mode of Action
  • 12.3. Market Attractiveness Analysis
    • 12.3.1. By Country
    • 12.3.2. By Class
    • 12.3.3. By Indication
    • 12.3.4. By Structures
    • 12.3.5. By Mode of Action
  • 12.4. Key Takeaways

13. Asia Pacific Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 13.2.1. By Country
      • 13.2.1.1. China
      • 13.2.1.2. Japan
      • 13.2.1.3. South Korea
      • 13.2.1.4. Singapore
      • 13.2.1.5. Thailand
      • 13.2.1.6. Indonesia
      • 13.2.1.7. Australia
      • 13.2.1.8. New Zealand
      • 13.2.1.9. Rest of Asia Pacific
    • 13.2.2. By Class
    • 13.2.3. By Indication
    • 13.2.4. By Structures
    • 13.2.5. By Mode of Action
  • 13.3. Market Attractiveness Analysis
    • 13.3.1. By Country
    • 13.3.2. By Class
    • 13.3.3. By Indication
    • 13.3.4. By Structures
    • 13.3.5. By Mode of Action
  • 13.4. Key Takeaways

14. MEA Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 14.2.1. By Country
      • 14.2.1.1. GCC Countries
      • 14.2.1.2. South Africa
      • 14.2.1.3. Israel
      • 14.2.1.4. Rest of MEA
    • 14.2.2. By Class
    • 14.2.3. By Indication
    • 14.2.4. By Structures
    • 14.2.5. By Mode of Action
  • 14.3. Market Attractiveness Analysis
    • 14.3.1. By Country
    • 14.3.2. By Class
    • 14.3.3. By Indication
    • 14.3.4. By Structures
    • 14.3.5. By Mode of Action
  • 14.4. Key Takeaways

15. Key Countries Glycomic Therapeutics Market Analysis

  • 15.1. U.S.
    • 15.1.1. Pricing Analysis
    • 15.1.2. Market Share Analysis, 2024
      • 15.1.2.1. By Class
      • 15.1.2.2. By Indication
      • 15.1.2.3. By Structures
      • 15.1.2.4. By Mode of Action
  • 15.2. Canada
    • 15.2.1. Pricing Analysis
    • 15.2.2. Market Share Analysis, 2024
      • 15.2.2.1. By Class
      • 15.2.2.2. By Indication
      • 15.2.2.3. By Structures
      • 15.2.2.4. By Mode of Action
  • 15.3. Brazil
    • 15.3.1. Pricing Analysis
    • 15.3.2. Market Share Analysis, 2024
      • 15.3.2.1. By Class
      • 15.3.2.2. By Indication
      • 15.3.2.3. By Structures
      • 15.3.2.4. By Mode of Action
  • 15.4. Mexico
    • 15.4.1. Pricing Analysis
    • 15.4.2. Market Share Analysis, 2024
      • 15.4.2.1. By Class
      • 15.4.2.2. By Indication
      • 15.4.2.3. By Structures
      • 15.4.2.4. By Mode of Action
  • 15.5. Germany
    • 15.5.1. Pricing Analysis
    • 15.5.2. Market Share Analysis, 2024
      • 15.5.2.1. By Class
      • 15.5.2.2. By Indication
      • 15.5.2.3. By Structures
      • 15.5.2.4. By Mode of Action
  • 15.6. U.K.
    • 15.6.1. Pricing Analysis
    • 15.6.2. Market Share Analysis, 2024
      • 15.6.2.1. By Class
      • 15.6.2.2. By Indication
      • 15.6.2.3. By Structures
      • 15.6.2.4. By Mode of Action
  • 15.7. France
    • 15.7.1. Pricing Analysis
    • 15.7.2. Market Share Analysis, 2024
      • 15.7.2.1. By Class
      • 15.7.2.2. By Indication
      • 15.7.2.3. By Structures
      • 15.7.2.4. By Mode of Action
  • 15.8. Spain
    • 15.8.1. Pricing Analysis
    • 15.8.2. Market Share Analysis, 2024
      • 15.8.2.1. By Class
      • 15.8.2.2. By Indication
      • 15.8.2.3. By Structures
      • 15.8.2.4. By Mode of Action
  • 15.9. Italy
    • 15.9.1. Pricing Analysis
    • 15.9.2. Market Share Analysis, 2024
      • 15.9.2.1. By Class
      • 15.9.2.2. By Indication
      • 15.9.2.3. By Structures
      • 15.9.2.4. By Mode of Action
  • 15.10. China
    • 15.10.1. Pricing Analysis
    • 15.10.2. Market Share Analysis, 2024
      • 15.10.2.1. By Class
      • 15.10.2.2. By Indication
      • 15.10.2.3. By Structures
      • 15.10.2.4. By Mode of Action
  • 15.11. Japan
    • 15.11.1. Pricing Analysis
    • 15.11.2. Market Share Analysis, 2024
      • 15.11.2.1. By Class
      • 15.11.2.2. By Indication
      • 15.11.2.3. By Structures
      • 15.11.2.4. By Mode of Action
  • 15.12. South Korea
    • 15.12.1. Pricing Analysis
    • 15.12.2. Market Share Analysis, 2024
      • 15.12.2.1. By Class
      • 15.12.2.2. By Indication
      • 15.12.2.3. By Structures
      • 15.12.2.4. By Mode of Action
  • 15.13. Singapore
    • 15.13.1. Pricing Analysis
    • 15.13.2. Market Share Analysis, 2024
      • 15.13.2.1. By Class
      • 15.13.2.2. By Indication
      • 15.13.2.3. By Structures
      • 15.13.2.4. By Mode of Action
  • 15.14. Thailand
    • 15.14.1. Pricing Analysis
    • 15.14.2. Market Share Analysis, 2024
      • 15.14.2.1. By Class
      • 15.14.2.2. By Indication
      • 15.14.2.3. By Structures
      • 15.14.2.4. By Mode of Action
  • 15.15. Indonesia
    • 15.15.1. Pricing Analysis
    • 15.15.2. Market Share Analysis, 2024
      • 15.15.2.1. By Class
      • 15.15.2.2. By Indication
      • 15.15.2.3. By Structures
      • 15.15.2.4. By Mode of Action
  • 15.16. Australia
    • 15.16.1. Pricing Analysis
    • 15.16.2. Market Share Analysis, 2024
      • 15.16.2.1. By Class
      • 15.16.2.2. By Indication
      • 15.16.2.3. By Structures
      • 15.16.2.4. By Mode of Action
  • 15.17. New Zealand
    • 15.17.1. Pricing Analysis
    • 15.17.2. Market Share Analysis, 2024
      • 15.17.2.1. By Class
      • 15.17.2.2. By Indication
      • 15.17.2.3. By Structures
      • 15.17.2.4. By Mode of Action
  • 15.18. GCC Countries
    • 15.18.1. Pricing Analysis
    • 15.18.2. Market Share Analysis, 2024
      • 15.18.2.1. By Class
      • 15.18.2.2. By Indication
      • 15.18.2.3. By Structures
      • 15.18.2.4. By Mode of Action
  • 15.19. South Africa
    • 15.19.1. Pricing Analysis
    • 15.19.2. Market Share Analysis, 2024
      • 15.19.2.1. By Class
      • 15.19.2.2. By Indication
      • 15.19.2.3. By Structures
      • 15.19.2.4. By Mode of Action
  • 15.20. Israel
    • 15.20.1. Pricing Analysis
    • 15.20.2. Market Share Analysis, 2024
      • 15.20.2.1. By Class
      • 15.20.2.2. By Indication
      • 15.20.2.3. By Structures
      • 15.20.2.4. By Mode of Action

16. Market Structure Analysis

  • 16.1. Competition Dashboard
  • 16.2. Competition Benchmarking
  • 16.3. Market Share Analysis of Top Players
    • 16.3.1. By Regional
    • 16.3.2. By Class
    • 16.3.3. By Indication
    • 16.3.4. By Structures
    • 16.3.5. By Mode of Action

17. Competition Analysis

  • 17.1. Competition Deep Dive
    • 17.1.1. Intellihep Ltd
      • 17.1.1.1. Overview
      • 17.1.1.2. Product Portfolio
      • 17.1.1.3. Profitability by Market Segments
      • 17.1.1.4. Sales Footprint
      • 17.1.1.5. Strategy Overview
        • 17.1.1.5.1. Marketing Strategy
    • 17.1.2. Protalix Biotherapeutics
      • 17.1.2.1. Overview
      • 17.1.2.2. Product Portfolio
      • 17.1.2.3. Profitability by Market Segments
      • 17.1.2.4. Sales Footprint
      • 17.1.2.5. Strategy Overview
        • 17.1.2.5.1. Marketing Strategy
    • 17.1.3. BioMarin Pharmaceutical Inc.
      • 17.1.3.1. Overview
      • 17.1.3.2. Product Portfolio
      • 17.1.3.3. Profitability by Market Segments
      • 17.1.3.4. Sales Footprint
      • 17.1.3.5. Strategy Overview
        • 17.1.3.5.1. Marketing Strategy
    • 17.1.4. Sanofi
      • 17.1.4.1. Overview
      • 17.1.4.2. Product Portfolio
      • 17.1.4.3. Profitability by Market Segments
      • 17.1.4.4. Sales Footprint
      • 17.1.4.5. Strategy Overview
        • 17.1.4.5.1. Marketing Strategy
    • 17.1.5. Halozyme Therapeutics Inc
      • 17.1.5.1. Overview
      • 17.1.5.2. Product Portfolio
      • 17.1.5.3. Profitability by Market Segments
      • 17.1.5.4. Sales Footprint
      • 17.1.5.5. Strategy Overview
        • 17.1.5.5.1. Marketing Strategy
    • 17.1.6. Bayer AG
      • 17.1.6.1. Overview
      • 17.1.6.2. Product Portfolio
      • 17.1.6.3. Profitability by Market Segments
      • 17.1.6.4. Sales Footprint
      • 17.1.6.5. Strategy Overview
        • 17.1.6.5.1. Marketing Strategy
    • 17.1.7. Alzheon Inc.
      • 17.1.7.1. Overview
      • 17.1.7.2. Product Portfolio
      • 17.1.7.3. Profitability by Market Segments
      • 17.1.7.4. Sales Footprint
      • 17.1.7.5. Strategy Overview
        • 17.1.7.5.1. Marketing Strategy
    • 17.1.8. GlycoMar
      • 17.1.8.1. Overview
      • 17.1.8.2. Product Portfolio
      • 17.1.8.3. Profitability by Market Segments
      • 17.1.8.4. Sales Footprint
      • 17.1.8.5. Strategy Overview
        • 17.1.8.5.1. Marketing Strategy
    • 17.1.9. GlaxoSmithKline Plc
      • 17.1.9.1. Overview
      • 17.1.9.2. Product Portfolio
      • 17.1.9.3. Profitability by Market Segments
      • 17.1.9.4. Sales Footprint
      • 17.1.9.5. Strategy Overview
        • 17.1.9.5.1. Marketing Strategy
    • 17.1.10. F. Hoffmann-La Roche Ltd
      • 17.1.10.1. Overview
      • 17.1.10.2. Product Portfolio
      • 17.1.10.3. Profitability by Market Segments
      • 17.1.10.4. Sales Footprint
      • 17.1.10.5. Strategy Overview
        • 17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology